Biotech Showcase™ 2019: Rexgenero advances CLI-focused regenerative medicine into Phase III

https://ebdgroup.knect365.com/biotech... Autologous cell therapy is finding traction as an effective approach to treating a number of serious but previously poorly-treated conditions. Joe Dupere, CEO at Rexgenero, reveals to Mike Ward during Biotech Showcase 2019 the four-year-old UK biotech’s plans to conduct two Phase III trials of REX-001 for both Category 4 and Category 5 critical limb ischemia.